PATH has received a $120m grant from the Bill & Melinda Gates Foundation to further strengthen its PATH Center for Vaccine Innovation and Access (CVIA), which works across every stage of vaccine research, development, and introduction for diseases in low-resource settings.
Avadel Pharmaceuticals has entered into a license agreement with Serenity Pharmaceuticals, which grants Avadel the sole right to commercialize and further develop Noctiva in the US and Canada.
Scientists may have found a clue to why people living with HIV have double the likelihood of developing heart disease.
Genmab and Seattle Genetics announced that Seattle Genetics has exercised its option to co-develop tisotumab vedotin.
Gene therapy firm Regenxbio has signed an agreement to acquire US-based firm Dimension Therapeutics.
Grid Therapeutics has signed an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for cancer.
German company Evotec has completed the acquisition of US-based Aptuit.
Vicarius Pharma has secured a CHF21m ($21.8m) investment through a Series A preferred stock financing from private investors.
A new consortium, led by Oxford BioMedica, will take part in a two-year, £2m project focused on gene and cell therapy manufacturing.
Peregrine Pharmaceuticals has cut down its workforce by up to 20%, as part of its efforts to decrease costs and achieve overall profitability.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.